KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Amortization of Deferred Charges: 2009-2020

Historic Amortization of Deferred Charges for Novavax (NVAX) over the last 6 years, with Dec 2020 value amounting to $1.4 million.

  • Novavax's Amortization of Deferred Charges changed negligibly% to $356,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $1.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.4 million for FY2020, which is negligibly% changed negligibly from last year.
  • Latest data reveals that Novavax reported Amortization of Deferred Charges of $1.4 million as of FY2020, which was down 0.00% from $1.4 million recorded in FY2019.
  • In the past 5 years, Novavax's Amortization of Deferred Charges ranged from a high of $1.4 million in FY2017 and a low of $1.3 million during FY2016.
  • In the last 3 years, Novavax's Amortization of Deferred Charges had a median value of $1.4 million in 2020 and averaged $1.4 million.
  • Data for Novavax's Amortization of Deferred Charges shows a peak YoY rose of 9.12% (in 2017) over the last 5 years.
  • Yearly analysis of 5 years shows Novavax's Amortization of Deferred Charges stood at $1.3 million in 2016, then grew by 9.12% to $1.4 million in 2017, then remained steady at $1.4 million in 2018, then remained steady at $1.4 million in 2019, then remained steady at $1.4 million in 2020.